Biopharmaceutical / Clinical-stage Oncology and Immunology
Strategic Profile
The company is currently enrolling patients in a pivotal Phase III clinical study evaluating Namodenoson for advanced hepatocellular carcinoma in patients with Child-Pugh B7 liver function, a patient population with no approved therapies currently available. The company's lead drug candidate Piclidenoson reported topline results in a Phase III trial for psoriasis and commenced a pivotal Phase III trial. The company has orphan drug and fast-track designations from the FDA for multiple programs.
Cyborg Score Rationale
Can-Fite is advancing multiple Phase III programs with FDA and EMA regulatory support, including orphan drug designations. Recent clinical data showing 9-year disease-free survival in liver cancer is notable. However, the company faced a 1-for-3,000 reverse stock split in January 2026, cash position decreased to $7.88M, and history of losses create execution and funding risks.
Top Insights
In January 2026, patient enrollment was completed in a Phase 2a pancreatic cancer clinical trial of Namodenoson, with efficacy data expected in Q3 2026
A patient with advanced liver cancer treated with Namodenoson achieved 9-year overall survival with complete response, including cancer-free status and normal liver function
An interim analysis from the Phase III HCC study is expected in approximately Q4 2026
The company executed a 1-for-3,000 reverse stock split effective January 5, 2026, indicating significant dilution and share price pressure historically
Named Competitors
Sorafenib and other tyrosine kinase inhibitors — Established HCC treatments for other patient populations
Biologics for psoriasis/inflammatory disease — TNF inhibitors and IL-inhibitors for inflammatory diseases
Small molecule oncology programs — Other clinical-stage cancer candidates
Recent Developments
(February 2026) Patient with decompensated liver cirrhosis successfully underwent transplantation following Namodenoson treatment
(January 2026) Completed patient enrollment in Phase 2a pancreatic cancer trial with safety profile demonstrated
(December 2025) Reverse stock split 1-for-3,000 executed; provided clinical development and financial status update
(November 2025) Announced 9-year complete survival case with liver cancer patient on Namodenoson
Open the full interactive Can-Fite BioPharma Ltd. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.